Frontotemporal dementia (FTD) is a significant cause of early-onset dementia, second only to Alzheimer's disease in this category1 . It primarily affects adults aged 45 to 65 and presents with diverse symptoms including behavioral changes and language difficulties2 . Despite its impact, FTD remains underrecognized, leading to diagnostic delays and challenges in clinical management3 . The recent diagnosis of Wendy Williams with primary progressive aphasia, a subtype of FTD, has brought renewed attention to this complex neurodegenerative disorder4 .
Early diagnosis of frontotemporal dementia is critical for patient care and planning, yet it remains challenging due to the disease’s heterogeneous presentation and lack of specific biomarkers. Increased awareness and use of neuroimaging tools like MRI can improve diagnostic accuracy12 35.
Increased Awareness and Diagnosis Rates
Frontotemporal dementia (FTD) is a progressive neurodegenerative condition characterized by selective degeneration of the frontal and/or temporal lobes of the brain5 6. This degeneration leads to a wide range of clinical symptoms including behavioral changes, executive dysfunction, and language impairments7 3. FTD encompasses several clinical variants, notably the behavioral variant (bvFTD) and primary progressive aphasias (PPA), which include semantic and nonfluent/agrammatic subtypes3 .
FTD accounts for up to 10% of all dementias with onset before age 65, making it the second most common cause of young-onset dementia after Alzheimer's disease1 8. However, prevalence estimates vary widely, ranging from 0.01 to 4.6 per 1,000 persons, reflecting diagnostic challenges and regional differences9 . The pooled incidence rate of FTD is approximately 2.28 per 100,000 person-years, with a pooled prevalence of 9.17 per 100,000 people3 10. These figures suggest that FTD is comparable in frequency to dementia with Lewy bodies and occurs more frequently than progressive supranuclear palsy, corticobasal syndrome, and amyotrophic lateral sclerosis3 .
Frontotemporal dementia often presents with symptoms that resemble psychiatric disorders, causing many patients to be misdiagnosed initially. This overlap contributes to significant delays in receiving an accurate diagnosis, sometimes extending up to 10 years11 23.
One major factor contributing to underdiagnosis is the overlap of FTD symptoms with psychiatric disorders. Approximately 50% of patients with bvFTD initially receive a psychiatric diagnosis, leading to an average diagnostic delay of 5 to 6 years11 3. This misdiagnosis is compounded by the existence of bvFTD phenocopies—patients who show behavioral symptoms without neuroimaging or pathological evidence of frontotemporal lobar degeneration, remaining clinically stable over time11 3. These complexities highlight the need for increased awareness among healthcare professionals to improve early and accurate diagnosis.
Diagnosis of FTD relies on a combination of clinical assessment, neuropsychological testing, and neuroimaging, with magnetic resonance imaging (MRI) being the most commonly used tool to detect frontal and temporal lobe atrophy5 12. Two general testing strategies are employed: one estimates premorbid cognitive abilities to detect decline in patients with mild deficits, and the other uses cognitive screening to identify dementia-level impairments13 . Despite these tools, the prodromal phase of FTD remains poorly characterized, and predictors of progression are still under investigation14 .
Greater awareness and understanding of FTD can lead to improved diagnosis rates. In Latin America, for example, FTD prevalence is estimated at 12–18 cases per thousand persons but is likely underestimated due to low awareness even among healthcare providers15 16. Early and accurate diagnosis is essential for appropriate clinical management and support, as FTD is a devastating condition with no effective disease-modifying treatments currently available17 3.
💡 Did You Know?
The estimated point prevalence of frontotemporal dementia ranges from 15 to 22 cases per 100,000 people, with an incidence of 2.7 to 4.1 per 100,000 annually. About 25% of cases have late-life onset, and population studies show nearly equal distribution across sexes20 .
The case of Wendy Williams, who was diagnosed with primary progressive aphasia and frontotemporal dementia in May 2023, underscores the importance of comprehensive medical and neuropsychological evaluations in confirming FTD diagnoses4 18. Her diagnosis followed extensive testing and brain imaging, highlighting the complexity of identifying this condition18 . Since FTD can lead to significant cognitive impairment, legal guardianship may be necessary to manage healthcare and financial decisions, as seen in Williams' case18 .
- Behavioral changes including disinhibition, apathy, and loss of empathy3 19
- Language impairments such as word-finding difficulties and progressive aphasia5 3
- Executive dysfunction affecting planning and decision-making7 3
- Psychiatric symptoms that may mimic depression, mania, or other mood disorders19
- Memory deficits, although typically less prominent than in Alzheimer's disease3 19
- Symptom overlap with psychiatric disorders leading to misdiagnosis11 3
- Phenocopy cases complicating clinical differentiation11
- Variability in clinical presentation depending on lobar involvement19
- Limited awareness among healthcare professionals, especially in underrepresented regions15 16
- Delays in diagnosis averaging 2.4 to 6 years, requiring multiple clinical consultations2
